Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY-GENE trial of early candesartan versus placebo in asymptomatic genetic carriers at risk for dilated cardiomyopathy
NL-OMON59344Phase 3Recruiting
- Sponsor
- Fundación de Investigación Biomédica Hospital Puerta de Hierro
- Start
- Nov 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing Candesartan cilexetil with Placebo (2 arms). Started Nov 2024; status: recruiting.
02
Drugs
candesartan cilexetil
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NL-OMON59344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59344.